Modeling the impact of modified directly observed antiretroviral therapy on HIV suppression and resistance, disease progression, and death

C. R. Kagay, T. C. Porco, C. A. Liechty, E. Charlebois, R. Clark, D. Guzman, A. R. Moss, David Bangsberg

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

A simulation model that used Markov assumptions with Monte Carlo uncertainty analysis was evaluated 1500 times at 10,000 iterations. Modified directly observed therapy (MDOT) for human immunodeficiency virus was assumed to improve adherence to therapy to 90% of prescribed doses. The impact of MDOT interventions on modeled biological and clinical outcomes was compared for populations with mean rates of adherence (i.e., the mean percentage of prescribed doses taken by each member of the population who had not discontinued therapy) of 40%, 50%, 60%, and 70%. MDOT reduced the risk of virological failure, development of opportunistic infections, and death, yet increased the risk of drug resistance, for each adherence distribution among persons with detectable plasma virus loads. Over 1500 trials, for a population with 50% adherence to therapy and a 12-month period, MDOT increased the median rate of virological suppression from 13.2% to 37.0% of patients, decreased the rate of opportunistic infection from 5.7% to 4.3% of patients, and decreased the death rate from 2.9% to 2.2% of patients. In the same population, however, MDOT increased the rate of new drug resistance mutations from 1.00 to 1.41 per person during the 12-month period. The impact of MDOT was smaller in populations with higher levels of adherence. MDOT interventions will likely improve clinical outcomes in populations with low levels of adherence but may not be effective at preventing drug resistance in treatment-experienced populations. MDOT may be more effective in preventing drug resistance with potent regimens in treatment-naive patients.

Original languageEnglish (US)
JournalClinical Infectious Diseases
Volume38
Issue numberSUPPL. 5
DOIs
StatePublished - Jun 1 2004
Externally publishedYes

Fingerprint

Directly Observed Therapy
Disease Progression
HIV
Drug Resistance
Population
Opportunistic Infections
Therapeutics
Uncertainty
Viruses
Mutation

ASJC Scopus subject areas

  • Immunology

Cite this

Modeling the impact of modified directly observed antiretroviral therapy on HIV suppression and resistance, disease progression, and death. / Kagay, C. R.; Porco, T. C.; Liechty, C. A.; Charlebois, E.; Clark, R.; Guzman, D.; Moss, A. R.; Bangsberg, David.

In: Clinical Infectious Diseases, Vol. 38, No. SUPPL. 5, 01.06.2004.

Research output: Contribution to journalArticle

Kagay, C. R. ; Porco, T. C. ; Liechty, C. A. ; Charlebois, E. ; Clark, R. ; Guzman, D. ; Moss, A. R. ; Bangsberg, David. / Modeling the impact of modified directly observed antiretroviral therapy on HIV suppression and resistance, disease progression, and death. In: Clinical Infectious Diseases. 2004 ; Vol. 38, No. SUPPL. 5.
@article{12fd3729553a4fd6a8e6a64fc269588a,
title = "Modeling the impact of modified directly observed antiretroviral therapy on HIV suppression and resistance, disease progression, and death",
abstract = "A simulation model that used Markov assumptions with Monte Carlo uncertainty analysis was evaluated 1500 times at 10,000 iterations. Modified directly observed therapy (MDOT) for human immunodeficiency virus was assumed to improve adherence to therapy to 90{\%} of prescribed doses. The impact of MDOT interventions on modeled biological and clinical outcomes was compared for populations with mean rates of adherence (i.e., the mean percentage of prescribed doses taken by each member of the population who had not discontinued therapy) of 40{\%}, 50{\%}, 60{\%}, and 70{\%}. MDOT reduced the risk of virological failure, development of opportunistic infections, and death, yet increased the risk of drug resistance, for each adherence distribution among persons with detectable plasma virus loads. Over 1500 trials, for a population with 50{\%} adherence to therapy and a 12-month period, MDOT increased the median rate of virological suppression from 13.2{\%} to 37.0{\%} of patients, decreased the rate of opportunistic infection from 5.7{\%} to 4.3{\%} of patients, and decreased the death rate from 2.9{\%} to 2.2{\%} of patients. In the same population, however, MDOT increased the rate of new drug resistance mutations from 1.00 to 1.41 per person during the 12-month period. The impact of MDOT was smaller in populations with higher levels of adherence. MDOT interventions will likely improve clinical outcomes in populations with low levels of adherence but may not be effective at preventing drug resistance in treatment-experienced populations. MDOT may be more effective in preventing drug resistance with potent regimens in treatment-naive patients.",
author = "Kagay, {C. R.} and Porco, {T. C.} and Liechty, {C. A.} and E. Charlebois and R. Clark and D. Guzman and Moss, {A. R.} and David Bangsberg",
year = "2004",
month = "6",
day = "1",
doi = "10.1086/421406",
language = "English (US)",
volume = "38",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "SUPPL. 5",

}

TY - JOUR

T1 - Modeling the impact of modified directly observed antiretroviral therapy on HIV suppression and resistance, disease progression, and death

AU - Kagay, C. R.

AU - Porco, T. C.

AU - Liechty, C. A.

AU - Charlebois, E.

AU - Clark, R.

AU - Guzman, D.

AU - Moss, A. R.

AU - Bangsberg, David

PY - 2004/6/1

Y1 - 2004/6/1

N2 - A simulation model that used Markov assumptions with Monte Carlo uncertainty analysis was evaluated 1500 times at 10,000 iterations. Modified directly observed therapy (MDOT) for human immunodeficiency virus was assumed to improve adherence to therapy to 90% of prescribed doses. The impact of MDOT interventions on modeled biological and clinical outcomes was compared for populations with mean rates of adherence (i.e., the mean percentage of prescribed doses taken by each member of the population who had not discontinued therapy) of 40%, 50%, 60%, and 70%. MDOT reduced the risk of virological failure, development of opportunistic infections, and death, yet increased the risk of drug resistance, for each adherence distribution among persons with detectable plasma virus loads. Over 1500 trials, for a population with 50% adherence to therapy and a 12-month period, MDOT increased the median rate of virological suppression from 13.2% to 37.0% of patients, decreased the rate of opportunistic infection from 5.7% to 4.3% of patients, and decreased the death rate from 2.9% to 2.2% of patients. In the same population, however, MDOT increased the rate of new drug resistance mutations from 1.00 to 1.41 per person during the 12-month period. The impact of MDOT was smaller in populations with higher levels of adherence. MDOT interventions will likely improve clinical outcomes in populations with low levels of adherence but may not be effective at preventing drug resistance in treatment-experienced populations. MDOT may be more effective in preventing drug resistance with potent regimens in treatment-naive patients.

AB - A simulation model that used Markov assumptions with Monte Carlo uncertainty analysis was evaluated 1500 times at 10,000 iterations. Modified directly observed therapy (MDOT) for human immunodeficiency virus was assumed to improve adherence to therapy to 90% of prescribed doses. The impact of MDOT interventions on modeled biological and clinical outcomes was compared for populations with mean rates of adherence (i.e., the mean percentage of prescribed doses taken by each member of the population who had not discontinued therapy) of 40%, 50%, 60%, and 70%. MDOT reduced the risk of virological failure, development of opportunistic infections, and death, yet increased the risk of drug resistance, for each adherence distribution among persons with detectable plasma virus loads. Over 1500 trials, for a population with 50% adherence to therapy and a 12-month period, MDOT increased the median rate of virological suppression from 13.2% to 37.0% of patients, decreased the rate of opportunistic infection from 5.7% to 4.3% of patients, and decreased the death rate from 2.9% to 2.2% of patients. In the same population, however, MDOT increased the rate of new drug resistance mutations from 1.00 to 1.41 per person during the 12-month period. The impact of MDOT was smaller in populations with higher levels of adherence. MDOT interventions will likely improve clinical outcomes in populations with low levels of adherence but may not be effective at preventing drug resistance in treatment-experienced populations. MDOT may be more effective in preventing drug resistance with potent regimens in treatment-naive patients.

UR - http://www.scopus.com/inward/record.url?scp=2942558656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2942558656&partnerID=8YFLogxK

U2 - 10.1086/421406

DO - 10.1086/421406

M3 - Article

C2 - 15156432

AN - SCOPUS:2942558656

VL - 38

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - SUPPL. 5

ER -